Tumor reirradiation: Issues, challenges and perspectives for radiobiology.

Fiche publication

Date publication

septembre 2024

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges , Dr BURCKEL Hélène

Tous les auteurs :
Noël G, Bou-Gharios J, Burckel H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39327200

Résumé

The radiobiology of tumor reirradiation is poorly understood. It pertains to tumors and their sensitivity at the time of relapse, encompassing primary tumors, metastases, or secondary cancers developed in or proximal to previously irradiated tissues. The ability to control the pathology depends, in part, on understanding this sensitivity. To date, literature data remains limited regarding changes in the radiosensitivity of tissues after initial irradiation, and most proposals are based on conjecture. The response of healthy tissues at the site of irradiation raises concerns about radio-induced complications. Cumulative dose is likely a major factor in this risk, thus using equivalent dose calculations might help reduce the risk of complications. However, the correlation between mathematical equivalence formulas and clinical effects of radiobiological origin is weak, and the lack of knowledge of the alpha/beta (α/β) ratio of healthy tissues remains an obstacle to the extensive use of these formulas. However, tissues exposed to recovery dose may have a tolerance to irradiation much higher than assumed, thus further biological work remains to be developed. Also, the functionality of previously irradiated tissues could be useful in selecting the most suitable irradiation beams. Finally, research on the genomics of irradiated healthy tissues could improve the prediction of side effects and personalize radiotherapy.